SCHEMBL24254549

SCHEMBL24254549

CSc1cccc(NC(=O)Cc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.67
STAT3 P40763 1/20 0.67
MEN1 O00255 8/20 0.61
KMT2A Q03164 8/20 0.61
HTT P42858 3/20 0.60
MAPT P10636 6/20 0.57
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 2/20 0.55
MAOB P27338 1/20 0.55
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254547 0.86 MEN1 (0.58) SMN1; SMN2STAT3MEN1KMT2AHTT
SCHEMBL24254543 0.84 MEN1 (0.56) SMN1; SMN2STAT3MEN1KMT2AHTT
SCHEMBL29079372 0.83 SMN1; SMN2 (0.74) SMN1; SMN2STAT3MEN1KMT2AHTT
SCHEMBL8269613 0.82 KMT2A (0.65) SMN1; SMN2MEN1KMT2AHTTMAPT
SCHEMBL24254508 0.79 MEN1 (0.78) SMN1; SMN2MEN1KMT2AHTTMAPT
SCHEMBL4007599 0.78 MEN1 (0.74) SMN1; SMN2STAT3MEN1KMT2AHTT
SCHEMBL11679178 0.76 MEN1 (0.77) SMN1; SMN2STAT3MEN1KMT2AHTT
SCHEMBL28335090 0.76 MEN1 (1.00) SMN1; SMN2MEN1KMT2AHTTMAPT
SCHEMBL24254505 0.76 LMNA (0.79) SMN1; SMN2MEN1KMT2AHTTMAPT
SCHEMBL11820160 0.75 MEN1 (0.70) SMN1; SMN2MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed